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In Uganda, as in many parts of Africa, the majority of the population seek
treatment for malaria in drug shops as their first point of care; however,
parasitological diagnosis is not usually offered in these outlets. Rapid diagnostic
tests (RDTs) for malaria have attracted interest in recent years as a tool to
improve malaria diagnosis, since they have proved accurate and easy to perform
with minimal training. Although RDTs could feasibly be performed by drug shop
vendors, it is not known how much customers would be willing to pay for an
RDT if offered in these settings. We conducted a contingent valuation survey
among drug shop customers in Mukono District, Uganda. Exit interviews were
undertaken with customers aged 15 years and above after leaving a drug shop
having purchased an antimalarial and/or paracetamol. The bidding game
technique was used to elicit the willingness-to-pay (WTP) for an RDT and a
course of artemisinin-based combination therapy (ACT) with and without RDT
confirmation. Factors associated with WTP were investigated using linear
regression. The geometric mean WTP for an RDT was US$0.53, US$1.82 for a
course of ACT and US$2.05 for a course of ACT after a positive RDT. Factors
strongly associated with a higher WTP for these commodities included having
a higher socio-economic status, no fever/malaria in the household in the past
2 weeks and if a malaria diagnosis had been obtained from a qualified health
worker prior to visiting the drug shop. The findings further suggest that the WTP
for an RDT and a course of ACT among drug shop customers is considerably
lower than prevailing and estimated end-user prices for these commodities.
Increasing the uptake of ACTs in drug shops and restricting the sale of ACTs to
parasitologically confirmed malaria will therefore require additional measures.
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KEY MESSAGES
 The willingness-to-pay for a rapid diagnostic test (RDT) performed in a drug shop was for the majority of drug shop
customers lower than the expected end-user price.
 The average willingness-to-pay for a course of artemisinin-based combination therapy (ACT) among drug shop customers
was considerably higher than for an RDT but still lower than the current price of an ACT in drug shops.
 Increasing the uptake of ACTs in drug shops and restricting the sale of ACTs to parasitologically confirmed malaria will
most likely require additional measures.
 Further research is required to explore mechanisms to increase demand for RDT diagnosis prior to sale of ACTs in drug
shops.
Background
The most recent treatment guidelines for malaria from the
World Health Organization recommend prompt parasitological
confirmation of suspected malaria illness in all patients before
treatment where testing facilities are available (World Health
Organization 2010). Rapid diagnostic tests (RDTs) have at-
tracted interest in recent years as a tool to improve malaria
diagnosis since they have generally proved accurate (Abba et al.
2011), affordable, quick and relatively easy to perform with
minimal training. Proper use of RDTs may also contribute to
reduced drug wastage, improved treatment of non-malarial
fevers and reduce the risk of development of drug resistance
(Hopkins et al. 2009). Economic evaluations have suggested that
the use of RDTs can be cost-effective in some settings (Lubell
et al. 2008; Shillcutt et al. 2008). There has been a rapid increase
in the roll-out of RDTs in public health facilities, although
evidence suggests that some providers do not always adhere to
the test results, continuing to prescribe antimalarials despite
negative results (Hamer et al. 2007; Reyburn et al. 2008; Ansah
et al. 2010).
In most countries of Africa, large proportions of the popula-
tion utilize the private sector, and in particular drug shops, as
their first option for treatment of fever and malaria (Amexo
et al. 2004; Mota et al. 2009). Similar treatment-seeking
behaviour is seen in Uganda, where it is estimated that
around 50% of all distribution of antimalarials to end users is
through drug shops (ACTWatch 2009), yet surveys in early 2009
found that the first-line malaria treatment, artemisinin-based
combination therapies (ACTs), was in stock in only 8% of
private sector providers and that the sale of a range of older,
less effective antimalarials was still common (ACTWatch
2009; O’Connell et al. 2011). In addition, malaria diagnosis
in Ugandan drug shops is rarely based on a parasitological
diagnosis since microscopes are typically not available
(ACTWatch 2009) and RDTs have not yet been included in
the list of commodities that registered drug shops are allowed
to sell.
Given that a large proportion of Ugandans visit drug shops as
their first option for treatment, there is increasing interest in
improving malaria case management in these outlets. Uganda is
one of the eight countries piloting the Affordable Medicines
Facility – malaria (AMFm), which aims to increase access to
good quality affordable ACTs in the public, non-government
organization (NGO) and private sectors in malaria-endemic
countries through a manufacturer-level subsidy (Arrow et al.
2004; Laxminarayan and Gelband 2009). In this context the
possibility of introducing RDTs in drug shops in order to
improve the targeting of ACTs is also being considered.
However, it is not known whether the community would be
willing to pay for RDTs, and if so how much. RDTs are a
relatively new commodity in Uganda, being first introduced
into government health facilities in 2008. In contrast, ACTs
have been in use in government facilities since 2005.
In the only published ‘willingness-to-pay’ (WTP) study for an
RDT we could identify in an African setting (Uzochukwu et al.
2010), customers in Nigeria reported a WTP of 431 Naira
(US$3.32). However, no similar studies have been conducted
elsewhere in sub-Saharan Africa. The main objective of this
study was to determine the willingness-to-pay for an RDT for
malaria among customers in registered drug shops in Mukono
District, central Uganda, and to identify factors influencing the
price that customers are willing to pay. In addition, this study
explored the WTP for a course of ACT with and without
confirmation with an RDT. This study is nested within an
ongoing randomized community trial investigating the feasibil-
ity, acceptability and cost-effectiveness of introducing RDTs in
drug shops in Mukono District, Central Uganda.
Methods
Study site and population
The study was conducted in Mukono District in Central Uganda
over a period of 5 weeks in June–July 2009 during the peak of
the rainy season. Mukono District had an estimated population
of 808 000 in 2002 and is predominantly rural, with only 5% of
the population living in urban areas and 50% of the working
population classified as subsistence farmers (Uganda Bureau of
Statistics 2006).
Malaria, predominantly due to Plasmodium falciparum, is the
leading cause of morbidity and mortality in the district. The
area is considered hyper-endemic for malaria. An exit survey
conducted in 65 registered drug shops in Mukono District, after
the present study, between June and September 2010 estimated
a slide positivity rate of 27% amongst customers with fever
(unpublished survey data). In contrast to earlier studies in
Uganda in 2009 (ACTWatch 2009; O’Connell et al. 2011), the
survey in 2010 revealed that 71% of these drug shops reported
having ACTs in stock on the day of the survey. Almost
two-thirds (64%) of the drug shop employees visited knew that
the first-line malaria drug for uncomplicated malaria is an ACT,
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but less than one-third (29%) knew what an RDT was for.
Parasitological diagnosis was possible in only a minority of drug
shops since only 4 out 65 shops reported having a functioning
microscope and none stocked RDTs. Focus group discussions
conducted with community members and in-depth interviews
with drug shop vendors in Mukono in 2009 likewise found a
widespread awareness of ACTs, which were universally per-
ceived as being highly effective (unpublished data), but less
familiarity with RDTs (Mbonye et al. 2010; Chandler et al.
2011).
Survey methods
The general approach chosen was a contingent valuation survey
with a willingness-to-pay format. This approach was considered
appropriate for this study as RDTs were not well-known goods
at the time of the study. Contingent valuation is a method
designed to establish preferences among a group of individuals
for a commodity not presently available on the market, or for
commodities where the current price does not reflect its value
to individuals. A monetary value is captured from individuals
by asking them to imagine that the commodity in question is
available on the market and how much they would be
‘willing-to-pay’ (WTP) as a maximum to have the good, or
alternatively the minimum value they would be ‘willing-to-ac-
cept’ (WTA) for being deprived of the commodity (Klose 1999;
Smith 2003). Contingent valuation has been particularly popu-
lar for valuing environmental interventions since in this field
the problem of missing or non-functioning markets is pervasive
(Hanley et al. 2003), but this method has also been increasingly
used for valuing health services both in developed and in
developing countries in recent years (Whittington 1998; Smith
2003). Contingent valuation surveys have been conducted for a
wide range of health services including an AIDS vaccine (Bishai
et al. 2004), a malaria vaccine (Sauerborn et al. 2005), improved
child survival (Weaver et al. 1996), insecticide-treated mosquito
nets (Onwujekwe et al. 2008) and ACT (Wiseman et al. 2005).
While there is some empirical evidence supporting the ability of
contingent valuation to yield WTP figures which are good
predictors of actual WTP (Blumenschein et al. 2001; Onwujekwe
et al. 2001; Onwujekwe 2004), there is continuous debate on
various aspects such as the best elicitation techniques and a
range of possible biases (Klose 1999; Smith and Sach 2010).
An important component of contingent valuation is the
format for eliciting WTP. A range of different formats has been
used including open-ended questions, closed questions (‘take it
or leave it’) and the bidding game (Russell et al. 1995; Klose
1999; Smith 2000), but there is no consensus regarding a gold
standard for WTP elicitation in the literature (Klose 1999;
Onwujekwe 2004). For this study, a bidding game technique
was chosen because it was expected to have content validity
in the setting of Mukono where there is some room for
negotiating the price of most goods. In addition, a few
empirical studies have found the bidding game to be very
reliable (Whittington et al. 1992; Cho et al. 2000) and more
reliable than closed questions (Dong et al. 2003a; Onwujekwe
et al. 2005).
Following the general advice that the hypothetical choice
must be presented to a respondent as a realistic and plausible
situation as far as possible (Russell et al. 1995; Whittington
1998; Smith 2003), the survey was conducted as exit interviews
among drug shop customers seeking treatment for fever or
malaria.
The interviews were conducted by five field assistants who
had at least 7 years of schooling and undertook 5 days of
training in general interviewing skills, understanding and
performing an RDT and learning about the difference between
ACTs and other antimalarials. Two days were dedicated to
training on the bidding game technique, where interviewers
participated in role plays followed by discussions and agree-
ment on the best ways of presenting the scenarios and
conducting the bidding games. This ensured standardization
of bidding game elicitation among interviewers. They also
participated in the pretesting and revision of the tools before
actual field work.
The trained interviewers were placed near drug shops where
they observed all trades in drug shops. Customers who had
purchased an antimalarial and/or paracetamol for fever were
approached by the interviewers once the drug shop trade had
finished, and interviews were conducted in a quiet place near
the shop.
Data collection instrument
The contingent valuation questionnaire comprised three main
categories of questions. The first section described the purpose
of the study, sought verbal consent and established eligibility
through a set of screening questions. Individuals eligible for an
interview were customers of 15 years and above and who were
either a head of household, a spouse of the head of household
or respondents who in their own opinion ‘participated in
the decision on what to do if a member of the household
is suffering from fever’. If the customer was a child below
15 years, interviewers accompanied the child to his/her home to
perform the interview with an eligible family member.
The second category of questions captured information on
factors believed to influence the willingness-to-pay for an RDT
and treatment with ACT. These included questions on the
demographic and socio-economic background of the individual
as well as factors that had been found to influence willingness-
to-pay for different malaria preventive and treatment services in
previous studies. These included the presence of fever/malaria
among family members in the previous 2 weeks, distance from
home to a provider, travel time to a provider and whether a
diagnosis had been obtained prior to the visit to the drug shop
(Cho et al. 2000; Onwujekwe et al. 2004a; Wiseman et al. 2005;
Chase et al. 2009). Socio-economic status was assessed through
a list of questions about ownership of assets taken from the
2006 Uganda Demographic and Health Survey (Uganda Bureau
of Statistics and Macro International Inc. 2007). Responses
were used to develop a socio-economic status index using
principal component analysis (Filmer and Pritchett 2001; Vyas
and Kumarayanake 2006). Individuals were ranked according
to the index and grouped into quintiles.
The third section consisted of the willingness-to-pay elicit-
ation. Three hypothetical scenarios were described to the
respondent which involved them coming to a drug shop as a
patient with suspected malaria and being offered diagnostic
and/or treatment services. Respondents were asked to state
their willingness-to-pay for: (1) a course of ACT for an adult,
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(2) an RDT performed by the drug shop employee and (3) a
course of ACT for an adult after having purchased an RDT
which turned out to be positive. More details on the scenarios
are provided in the appendix. Scenarios 1 and 3 were
introduced in order to examine if there were systematic
differences in willingness-to-pay for a course of ACT according
to whether malaria had been confirmed by an RDT or not.
Interviewers were instructed to simulate an auction process:
first they presented the respondent with the starting offer and
asked her/him whether s/he was willing to pay that amount.
Respondents who were willing to pay the initial amount were
then asked about a higher offer. Bidding continued as long as
the response was still ‘‘yes’’. If the respondent said ‘‘no’’ to an
offer, the bidding process was stopped and respondents were
asked for the maximum they were willing to pay as an
open-ended question. The amount stated in the open-ended
question should logically lie between the last two offers and
interviewers were instructed to remind the respondents about
the last two offers. The starting offers were the same for all
respondents and set at a low level as judged by WTP answers
from the pilot test of the questionnaire [UGX500 (US$0.25) for
an RDT and UGX2000 (US$1.00) for a course of ACT]. After
each bidding game for eliciting WTP for the goods for an adult,
an open-ended question was posed to obtain the WTP for the
same goods for a child.
Sampling
A multi-stage sampling procedure was used to select the drug
shops. A list of all 17 census enumeration areas (EAs) for
Mukono district was obtained from the Uganda Bureau of
Statistics. All EAs with a health centre II were selected resulting
in 14 eligible EAs.1 For logistical convenience, five EAs were
randomly selected from this list. Using a list of drug shops
registered by the National Drug Authority, 25 drug shops were
randomly selected from the five EAs.
We calculated that a sample size of 500 exit interviews (20
per drug shop) would be needed to estimate the mean
willingness-to-pay for an RDT with a 95% confidence interval
of 15%, assuming a mean of UGX1600 (US$0.80), a standard
deviation of UGX1400 (US$0.70) and an intra-cluster correl-
ation of 0.15.
Ethical clearance
Ethical clearance for the study was obtained from the institu-
tional review board of the Uganda National Council for Science
and Technology, Kampala, in March 2009 (reference number
HS 546) and the Ethics Committee of the London School of
Hygiene and Tropical Medicine (application number 5709).
Statistical methods
Data were entered and verified in EpiData Entry version 3 (The
EpiData Association, Odense, Denmark) and analysed using
STATA version 10 (StataCorp, Texas, USA). Linear regression
was used to examine factors influencing customers’ WTP for an
RDT, a course of ACT and a course of ACT after a positive RDT,
respectively. Factors associated with WTP in the univariate
analyses (P 0.10) were included in a multivariable model. All
factors that remained significantly associated (P 0.10) and
with geometric mean ratios above 1.2 or below 0.8 in this
multivariable model were retained. These models were fitted to
the natural logarithm of the WTP values due to the distribu-
tions being right-skewed. The distributions of log transformed
WTP values were normally distributed. Results have been
transformed back onto the original scale, and geometric means
or ratios of geometric means are presented. Log-likelihood ratio
tests were used to compare the goodness of fit of the different
multivariable models. A paired t-test on log transformed WTP
answers was used for comparing the WTP for a course of ACT
and a course of ACT after a positive RDT.
Results
Demographic characteristics of respondents
Interviews were conducted with 519 customers visiting a
licensed drug shop. Sixteen per cent of interviews were
conducted in the respondent’s home. A similar number of
males (53%) and females (47%) participated in the interviews,
and two-thirds (68%) of customers were aged below 40 years.
Over half (52%) were educated up to primary school level and
the main occupation of the head of household was farming
(44%). The majority of respondents (95%) reported that it
would be useful if a test for malaria could be performed at drug
shops. Drug stock-outs at public facilities are a common
occurrence and thus approximately one-quarter (24%) of
those interviewed attended a drug shop with a prior diagnosis
of malaria determined by a laboratory test or presumptively by
a health worker. Most of the customers (87%) reported having
purchased at least one antimalarial during the present visit to
the drug shop, including quinine (32%), amodiaquine (21%),
sulphadoxine-pyrimethamine (18%) and chloroquine (18%),
but only 21 customers (4%) had purchased an antimalarial
drug containing artemisinin. The geometric mean of the
expenditure by drug shop customers on all drugs including
antimalarials, analgesics etc. was UGX1758 (US$0.87) on the
day of the interview.
Willingness-to-pay for an RDT and a course of ACT
Bidding games were completed by the majority of drug shop
customers to elicit their WTP for an RDT (99%), a course of ACT
(97%) and a course of ACT after a positive RDT (96%), and all
stated WTP replies were above zero. The geometric mean WTP
for an RDT was UGX1067 (US$0.53), with a considerably
higher WTP for a course of ACT of UGX3661 (US$1.82),
increasing to UGX4128 (US$2.05) for RDT-confirmed malaria
(Table 1). Almost two-thirds (63%) of the drug shop customers
stated that that they would be willing to pay the same for an
RDT for a child as for an adult. The majority of customers said
that they were willing to pay less for a course of ACT for a child
both without an RDT (85%) and with a prior RDT (82%).
Figure 1 displays the proportion of drug shop customers
willing to pay a given price or more for the proposed services.
The hypothetical demand for an RDT falls quickly as price
increases. For example, 64% of the drug shop customers have a
WTP of UGX1000 (US$0.50) or above, while only 26% of
customers have a WTP of UGX2000 (US$1.00) or above. The
hypothetical demand for ACTs falls more gradually and there is
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considerable overlap between the two curves for WTP for a
course of ACT with or without malaria confirmed by an RDT.
Among drug shop customers, 90% were willing to pay UGX2000
(US$1.00) or more for a course of ACT, while 93% were willing
to pay this amount or more for an ACT if malaria had been
confirmed by an RDT first. Similarly, 27% of customers were
willing to pay UGX6000 (US$2.99) or more for a course of ACT
and 32% were willing to pay this amount for an ACT after
confirmation of malaria by an RDT.
On average, the WTP for a course of ACT after a confirmation
of malaria was significantly higher than the WTP for an ACT
course without RDT confirmation (P< 0.001). However, only
33% of the drug shop customers reported a higher WTP for an
ACT if malaria had been confirmed by an RDT, with more than
half (58%) of customers stating the same WTP for a course of
ACT whether or not malaria was RDT-confirmed.
Factors affecting willingness-to-pay
Table 2 shows the univariate associations of demographic and
malaria factors with WTP for the three scenarios. A higher WTP
for an RDT was associated (P 0.10) with respondents
who were of younger age, female, had a higher level of
schooling, occupations other than farming and with higher
socio-economic status of the household. Customers with no
fever/malaria in the household in the previous 2 weeks and
those who had a prior malaria diagnosis given by a health
worker or a parasitological test before coming to the drug shop
were also more willing to pay a higher price for an RDT. All
factors, except gender and education, remained independently
associated with the same direction of association in the
multivariable analysis (Table 3).
Similar patterns of univariate associations were observed for
the WTP for a course of ACT with and without confirmation
with an RDT, with the addition of travel time such that
customers who travelled longer to a drug shop were more
willing to pay a higher price for an ACT. All factors, with the
exception of gender and education, remained independently
associated with the WTP for a course of ACT in the
multivariable analysis. For the WTP for a course of ACT
after a positive RDT, gender and occupation were no longer
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Figure 1 Relationship between price and the proportion of drug shop customersa willing to pay at least the presented price in UGX
(UGX2010¼US$1)b for an RDT, a course of ACT and a course of ACT after a positive RDT, Mukono District, June–July 2009 Notes: a5, 17 and 19
out of 519 drug shop customers had missing values or refused to state a WTP for an RDT, a course of ACT and a course of ACT after a positive RDT,
respectively. bAverage exchange rate during 2009 (www.oanda.com).
Table 1 Willingness-to-pay (WTP) in UGX (UGX2010¼US$1)a among 519 drug shop customers for an RDT, a course of ACT
and a course of ACT following a positive RDT, Mukono District, Uganda, June–July 2009
WTP for: No. of
responsesb
Geometric
mean (UGX)c
95% CI Geometric
mean (US$)c
95% CI
RDT 514 1067 [1006; 1132] 0.53 [0.50; 0.56]
ACT 502 3661 [3431; 3906] 1.82 [1.71; 1.94]
ACT after pos. RDT 500 4128 [3870; 4403] 2.05 [1.93; 2.19]
Notes: aAverage exchange rate during 2009 (www.oanda.com).
b5, 17 and 19 out of 519 drug shop customers had missing values or refused to state a WTP for an RDT, a course of ACT and a course of
ACT after a positive RDT, respectively.
cAntilog of the mean of log transformed WTP values.
CI¼Confidence Interval
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Table 2 Univariate associations of demographic and malaria factors with the willingness-to-pay for malaria diagnosis and treatment, Mukono
District, 2009
RDT (N¼ 514) Course of ACT (N¼ 502) Course of ACT after positive
RDT (N¼ 500)
na GMRb [95% CI] na GMRb [95% CI] na GMRb [95% CI]
Age group (years)
15–24 115 1.00** 114 1.00*** 115 1.00***
25–29 81 0.83 [0.68; 1.01] 77 0.90 [0.73; 1.11] 76 0.91 [0.73; 1.12]
30–34 77 0.82 [0.68; 1.00] 77 0.75 [0.60; 0.92] 75 0.85 [0.69; 1.04]
35–39 74 0.76 [0.63; 0.93] 73 0.76 [0.62; 0.94] 73 0.74 [0.60; 0.91]
40–49 81 0.79 [0.65; 0.96] 78 0.69 [0.56; 0.86] 78 0.72 [0.58; 0.88]
50þ 85 0.72 [0.60; 0.88] 82 0.67 [0.54; 0.82] 82 0.66 [0.54; 0.81]
Gender
Male 274 1.00* 268 1.00** 267 1.00**
Female 240 1.12 [0.99; 1.26] 234 1.19 [1.04; 1.35] 233 1.21 [1.06; 1.38]
Marital status
Married/cohabiting 386 1.00 375 1.00 373 1.00
Not in relationship 120 0.94 [0.82; 1.08] 119 0.92 [0.79; 1.07] 119 0.92 [0.79; 1.08]
Level of education
Primary 271 1.00** 268 1.00** 267 1.00**
O level 143 1.25 [1.09; 1.44] 140 1.26 [1.09; 1.47] 138 1.28 [1.10; 1.48]
A level and above 51 1.27 [1.04; 1.56] 48 1.20 [0.95; 1.50] 49 1.24 [0.99; 1.55]
None 49 1.11 [0.90; 1.36] 46 1.17 [0.93; 1.47] 46 1.20 [0.96; 1.51]
Occupationc
Farmer 224 1.00*** 219 1.00*** 219 1.00***
Labourer, craftsman 71 1.49 [1.25; 1.79] 70 1.61 [1.33; 1.96] 69 1.60 [1.32; 1.95]
Sales 99 1.13 [0.97; 1.33] 98 1.15 [0.97; 1.36] 97 1.15 [0.97; 1.37]
Services 80 1.23 [1.04; 1.46] 76 1.38 [1.14; 1.67] 75 1.30 [1.08; 1.57]
Unemployed, other 23 1.34 [1.01; 1.78] 22 1.79 [1.31; 2.45] 23 1.55 [1.14; 2.11]
Socio-economic status
Lowest 104 1.00*** 101 1.00*** 101 1.00***
Lower middle 102 1.07 [0.89; 1.29] 99 1.22 [1.00; 1.49] 100 1.14 [0.93; 1.39]
Middle 101 1.17 [0.97; 1.41] 101 1.16 [0.95; 1.42] 101 1.17 [0.96; 1.42]
Upper middle 103 1.28 [1.07; 1.54] 100 1.44 [1.18; 1.77] 100 1.46 [1.20; 1.78]
Highest 102 1.48 [1.23; 1.78] 99 1.63 [1.33; 1.99] 96 1.63 [1.34; 2.00]
Malaria in household in the past 2 weeks
Presence of malaria 433 1.00*** 427 1.00*** 425 1.00***
No malaria 28 1.61 [1.25; 2.08] 26 1.77 [1.33; 2.35] 26 1.78 [1.34; 2.36]
Malaria diagnosis prior to drug shop visitd
No 388 1.00*** 379 1.00** 377 1.00**
Yes 126 1.46 [1.27; 1.66] 123 1.28 [1.10; 1.48] 123 1.24 [1.06; 1.43]
Travel time to drug shop
Less than 1 hour 330 1.00 324 1.00** 322 1.00*
1 hour or above 118 1.12 [0.97; 1.29] 113 1.20 [1.02; 1.40] 113 1.17 [1.00; 1.36]
Travel distance to drug shop
Less than 1 km 137 1.00 136 1.00 134 1.00
1–3 km 139 0.94 [0.80; 1.10] 138 1.01 [0.85; 1.20] 138 1.07 [0.90; 1.27]
3 km or more 181 1.04 [0.90; 1.21] 173 1.09 [0.93; 1.29] 173 1.07 [0.91; 1.25]
Notes: *P 0.10; **P 0.05; ***P 0.001.
aThe number of respondents by category in each variable may not add to N due to non-responses.
bGMR stands for geometric mean ratio.
cSales included shopkeeper, retail, wholesale, market vendor. Services included civil servant, driver, security guard, boda boda rider.
d‘No’ indicates patient self-diagnosis or diagnosis without a test by drug seller during the drug shop visit; ‘Yes’ indicates laboratory test or presumptive
diagnosis by health worker prior to the drug shop visit.
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associated after adjusting for the other demographic and
malaria factors.
Discussion
The present contingent valuation survey was designed to
elicit the willingness-to-pay for an RDT and a course of
ACT among individuals choosing to visit drug shops for
malaria treatment in Uganda. The results may help to set
the initial prices in the private sector for their present
customers. While it must be emphasized that the WTP values
found in this study may not be generalizable to the
population as a whole, the findings may nevertheless be
used to draw some general recommendations on public health
policy related to the RDTs and ACTs supplied through drug
shops in Uganda.
Table 3 Multivariable linear regression analysis between willingness-to-pay among drug shop customers for
malaria diagnosis and treatment and selected factors, Mukono District, 2009
RDT Course of ACT Course of ACT after
positive RDT
GMRa [95% CI] GMRa [95% CI] GMRa [95% CI]
Age group (years)
15–24 1.00** 1.00* 1.00**
25–29 0.79 [0.65; 0.96] 0.87 [0.70; 1.08] 0.88 [0.71; 1.10]
30–34 0.88 [0.72; 1.07] 0.86 [0.68; 1.08] 0.95 [0.75; 1.19]
35–39 0.74 [0.60; 0.90] 0.85 [0.68; 1.06] 0.72 [0.58; 0.90]
40–49 0.79 [0.65; 0.96] 0.75 [0.59; 0.95] 0.75 [0.60; 0.94]
50þ 0.76 [0.62; 0.92] 0.73 [0.59; 0.92] 0.68 [0.55; 0.84]
Level of education
Primary 1.00*
O level 1.07 [0.91; 1.27]
A level and above 1.01 [0.80; 1.29]
None 1.38 [1.08; 1.77]
Occupationb
Farmer 1.00** 1.00**
Labourer, craftsman 1.28 [1.06; 1.54] 1.33 [1.07; 1.65]
Sales 0.94 [0.79; 1.10] 1.02 [0.84; 1.23]
Services 0.97 [0.81; 1.16] 1.09 [0.89; 1.35]
Unemployed, other 1.09 [0.81; 1.47] 1.62 [1.13; 2.33]
Socio-economic status
Lowest 1.00** 1.00** 1.00**
Lower middle 1.04 [0.86; 1.24] 1.10 [0.89; 1.37] 1.08 [0.88; 1.34]
Middle 1.11 [0.91; 1.34] 1.12 [0.89; 1.40] 1.11 [0.89; 1.38]
Upper middle 1.20 [0.99; 1.45] 1.33 [1.06; 1.67] 1.29 [1.03; 1.63]
Highest 1.38 [1.14; 1.68] 1.53 [1.21; 1.93] 1.53 [1.20; 1.96]
Malaria in household in the past 2 weeks
Presence of malaria 1.00*** 1.00*** 1.00***
No malaria 1.67 [1.31; 2.13] 1.80 [1.35; 2.40] 1.99 [1.50; 2.64]
Malaria diagnosis prior to drug shop visitc
No 1.00*** 1.00** 1.00**
Yes 1.42 [1.24; 1.63] 1.24 [1.07; 1.45] 1.19 [1.02; 1.39]
Travel time to drug shop
Less than 1 hour 1.00*** 1.00**
1 hour or above 1.38 [1.17; 1.63] 1.30 [1.10; 1.53]
Notes: *P 0.10; **P 0.05; ***P 0.001.
aGMR stands for geometric mean ratio.
bSales included shopkeeper, retail, wholesale, market vendor. Services included civil servant, driver, security guard, boda
boda rider.
c‘No’ indicates patient self-diagnosis or diagnosis without a test by drug seller during the drug shop visit; ‘Yes’ indicates
laboratory test or presumptive diagnosis by health worker prior to the drug shop visit.
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The results of our study suggest that the WTP for an RDT and
the WTP for a course of ACT are low and likely to be
considerably lower than unsubsidized end-user prices of these
commodities. Currently the unsubsidized price of an RDT in
drug shops is likely to be in the range of UGX5220–5800
(US$2.54–2.83). This estimate is based on the price offered to
both the public and the private sectors by one large Ugandan
supplier (Joint Medical Stores 2009) of UGX2900 (US$1.41)
including value added tax (VAT) and costs of insurance and
freight at the time of the study, and assuming a mark-up of 80–
100% as suggested by a survey among drug shops in nine
districts (Medicines for Malaria Venture 2008) and in Mukono
District (unpublished data). This price was considerably higher
than the WTP for an RDT found among most customers in our
study where only 4% of the respondents were willing to pay
UGX5000 (US$2.49) or more. In order to ensure that many
more drug shop customers would be willing to buy an RDT, the
price would need to be much lower. Theoretically the price of
an RDT should be as low as UGX700 (US$0.35) to ensure that
three-quarters of our study participants would be willing to
purchase an RDT. Similarly, the average price of an adult course
of ACT was UGX15000 (US$7.46) in drug shops in Mukono
District at the time of the study (unpublished data), while a
country-wide survey found a median price of UGX9000
(US$4.48) (O’Connell et al. 2011). Our results indicate that
only 4% and 13% of customers would purchase a course of ACT
at these prices and that the price of a course of ACT needed to
be as low as UGX2500 (US$1.24) to ensure that 69% of the
respondents would purchase this antimalarial. ACTs through
the AMFm facility will be made available to customers at a
recommended retail price printed on the package of UGX800
(US$0.40) for an adult course. This is double the price of
US$0.18 for an adult course of sulphadoxine-pyrimethamine,
the most popular antimalarial in Uganda at the time of the
study (ACTWatch 2009). Our results suggest that a price of
UGX800 for an adult course of ACT would nevertheless still
ensure that almost all drug shop customers (99%) in the
present survey would purchase this treatment.
The results from our survey suggest that the WTP for both an
RDT and a course of ACT is much lower than likely market prices.
With the implementation of the AMFm, good quality ACTs should
be available in drug shops at low prices (Sabot et al. 2009).
However, there are concerns that this will give rise to a marked
increase in the use of ACTs by those who do not need them. If the
uptake of RDTs in drug shops is to be encouraged in order to
improve the targeting of the subsidized ACTs then they too will
need to be subsidized; our results indicate that the subsidy will
need to be at a level that will ensure that the price of RDTs is
substantially lower than that of the ACTs. In Cambodia, where
there has been a nationwide programme of subsidized, socially
marketed RDTs and ACTs for almost 10 years, the subsidized
wholesale price of RDTs was recently reduced to US$0.05 per test,
with a recommended retail price (RRP) of US$0.24, in order to
incentivize the use of RDTs. This compares with a wholesale price
of US$0.42 and RRP of US0.61 for an adult course of recom-
mended ACT (Yeung et al. 2011).
The WTP for an RDT was found to be much lower than the
WTP for a course of ACT. In addition, the WTP for a course of
ACT after having purchased an RDT confirming malaria was
not much higher than the WTP for ACT without parasitological
confirmation. A number of factors may have contributed to the
lower expressed WTP for an RDT. In contrast to ACTs which
were well known and perceived to be highly efficacious
and superior to other antimalarials by the local community
(unpublished report), RDTs were generally not well known
(Mbonye et al. 2010; Chandler et al. 2011) and it may have been
more difficult for interviewees to place a value on a commodity
that was unfamiliar. In addition, ACTs are currently priced
much higher than other antimalarials and thus the customer
may expect that all of the funds they have available may be
needed for the drug purchase. As the RDT represents a cost in
addition to the cost of medication, it may be perceived as
unaffordable if the customer believes that the fever is probably
due to malaria or that the best way to diagnose a disease is by
trying different drugs until one of these removes symptoms
(Chandler et al. 2011). Should these beliefs change, or the price
of ACT drop, the WTP for an RDT might change.
Nonetheless, the findings of our study suggest that drug shop
customers currently place a very low value on seeking parasito-
logical confirmation from an RDT before purchasing an antimal-
arial and additional measures may be necessary to encourage use
of RDTs. Further research is thus needed to investigate and
develop specific mechanisms to increase demand for RDT diag-
nosis prior to sale of ACTs in drug shops. Possible approaches
include the use of targeted subsidies and/or offering the RDT and
ensuing treatment as a single bundled commodity rather than two
separate commodities. For instance, a possible package of diag-
nosis and treatment could incorporate a proposal to a customer to
purchase an RDT after which the customer will be offered a course
of ACT for free or at a low price if the test is positive, and another
appropriate treatment or advice to seek treatment at a health
centre if the test is negative. As this type of package or ‘conditional
sale’ of an antimalarial is not normally offered in drug shops, a
specific system would need to be set up. A recent study in Kenya
explored the use of a voucher system through which the study
population could access RDTs and ACTs at different prices (Cohen
et al. 2011). One of the packages offered a full refund of the RDT if
it was positive and the customer purchased an ACT. Our findings
lend support to the need to develop novel interventional mech-
anisms in order to promote diagnosis in drug shops, and to
investigate their feasibility and cost-effectiveness.
The analysis of factors influencing the WTP for malaria
diagnosis and treatment showed some variation across different
groups in this study. Most notably the WTP increased with the
socio-economic quintiles. The implication of this is that relatively
low prices of an RDT and a course of ACT are needed to ensure that
the poorest sections of drug shop customers will purchase
diagnosis and treatment at drug shops. This may be achieved
through a high subsidy. Experience of fever or malaria in the
household in the previous 2 weeks resulted in a lower WTP for
malaria diagnosis and treatment than if no fever or malaria had
been experienced. Similar findings regarding a negative associ-
ation between experience with malaria and WTP for malaria
services have been reported in other studies (Onwujekwe et al.
2004b; Udezi et al. 2010). Possible explanations for the association
in our study could be that households with a recent experience
with fever or malaria still had leftover medication or the fevers
experienced were mild or self-resolving. Finally, the associations
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found in this study could be used for identifying groups to be
targeted for an information campaign on the benefits of para-
sitological diagnosis and ACT. The focus could be on groups which
currently have low valuations of RDT diagnosis and ACT such as
older age groups and certain occupational groups.
The present contingent valuation survey resulted in plausible
WTP values for an RDT and a course of ACT among drug shop
customers in Uganda. For instance, the stated WTP for an ACT
was not unrealistically higher than the actual expenditure on
drugs purchased on the day of the interview (geometric mean
of US$1.82 vs US$0.87). It would be expected that the WTP for
an ACT is higher than for other antimalarials as the former was
described to the respondents as being the most effective. In
addition, the WTP for an adult course of ACT was much lower
than the actual price of an ACT at the time of the study when a
country-wide survey found a median price of UGX9000
(US$4.48) (O’Connell et al. 2011), while a more recent survey
found a median price of US$1.92 for an adult course of ACT
(Health Action International 2011). Nevertheless, a number of
potential limitations of the study should be mentioned.
The validity of the contingent valuation technique has been
the subject of much discussion and possible biases have been
identified which may drive a wedge between hypothetical and
actual WTP (Klose 1999). Hypothetical bias may arise if
respondents feel that the scenarios described to them are too
hypothetical and therefore they may not take the task
presented to them seriously (Onwujekwe et al. 2005).
However, it is not clear if hypothetical bias would lead to an
underestimate or overestimate of the stated WTPs in this study.
In order to minimize this kind of bias, this study tried to
simulate as much as possible a realistic and plausible choice
situation, for instance by conducting WTP interviews with
customers just exiting a drug shop after the purchase of
treatment for fever. Starting-point bias refers to the phenom-
enon whereby respondents’ WTP is influenced by the opening
offer and is typically measured by giving different opening
offers to different sub-samples of respondents (Dong et al.
2003b). While the extent of starting-point bias was not
measured as part of the present study, there are some
indications that this might not have been a serious problem.
The opening offers in the bidding games were the same for all
respondents and set at low values of UGX500 (US$0.25) for an
RDT and UGX2000 (US$1.00) for a course of ACT. It was
observed during the bidding games that the number of
additional offers accepted after the opening bid varied a lot
among the respondents, suggesting a deliberate thought process
on one’s WTP rather than applying some mechanical process
such as accepting the first 2–3 bids and then declining.
However, if starting-point bias was a problem, the WTP
values obtained might be underestimates of actual WTP since
the opening bid was low. Contingent valuation exercises with
valuation of several different commodities may experience
order-effect bias whereby the order of presentation of commod-
ities to be valued has an influence on the valuation of individual
goods. As recommended by several authors (Bateman and
Langford 1997; Clark and Friesen 2008), we attempted to
minimize the order-effect bias by explaining the full range of
goods to be valued during the interview before any elicitation
started.
Conclusions
The findings of the present study suggest that the willingness-
to-pay for an RDT and an ACT among drug shop customers is
considerably lower than prevailing and estimated prices for
these goods. If the dual objectives of increasing the uptake of
ACTs in drug shops and restricting the prescription of ACTs
to parasitologically confirmed malaria are to be achieved,
additional interventions will therefore be necessary. The
AMFm initiative aims to provide ACTs at low prices through
a subsidy. Increased utilization of RDTs may likewise
be encouraged through a subsidy large enough to ensure a
price considerably lower than the price of a course of ACT.
Other approaches such as the introduction of diagnosis and
treatment as a single bundled commodity rather than two
separate commodities could be a relevant topic for further
research.
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Endnote
1 The presence of a health centre in an EA was not required for the
present contingent valuation survey, but this was an important
component for the main trial investigating the feasibility, accept-
ability and cost-effectiveness of introducing RDTs in drug shops in
Mukono District.
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Appendix
Hypothetical scenarios presented to respondents before asking their
willingness-to-pay, Mukono District, 2009
Scenario 1: A course of ACT
Assume that you have come to a drug shop today because you think that you may have malaria although you have not taken a test.
I will now give you some additional information on some new malaria drugs.
The Ministry of Health of Uganda now recommends drugs called artemisinin combination therapies or ‘ACTs’, for example Co-artem,
for treating malaria. This is because it is a combination of two drugs and cures people more quickly and more effectively than the
older antimalarials like chloroquine and fansidar. (Interviewer: show package of Co-artem.)
The Ministry of Health wishes to make ACTs such as Co-artem widely available to the population of Uganda. Private drug sellers
cannot offer services for free—they have to charge a price. For this study, it is important to know how valuable Co-artem is for
potential customers like yourself.
I will now ask you some questions on what you might do if Co-artem had been available in drug shops today. I want to know if you
would consider buying Co-artem from drug sellers, and if yes, how much you would value this drug. I will give different examples of
prices for Coartem and then ask you if you would buy a full dose of Co-artem at that price.
If drug shops had Co-artem available today—would you be willing to pay UGX2000 for a course of Co-artem to treat one attack of
malaria?
Scenario 2: Rapid diagnostic test (RDT)
Assume that you have come to a drug shop today because you think that you may have malaria although you have not taken a test.
Diagnosis of malaria can be difficult. If you suffer from fever or headache, this may be a sign of malaria which should be treated
with antimalarial drugs. However, these symptoms may just as well be another health problem which should be treated with
something else. Malaria is caused by parasites in your blood so the best way of finding out if you have malaria is to examine your
blood for parasites. In the past this could only be done by using a microscope and was therefore only done in hospitals and some
health centres. However, now there is a new simple test to look for malaria parasites which can be performed anywhere and takes
about 15 minutes to get the result. This test requires only a drop of blood taken from the finger so this is similar to the way it is done
at a health facility when blood is taken for examination using a microscope. Since the test kit will only be used once there is no risk
of transmission of diseases during the taking of a drop of blood. In addition, the test can only be used to diagnose malaria and no
other disease. The test must be performed by a trained drug seller or a trained health worker. Therefore, an ill person must travel
from home to a drug seller or health facility if he/she wants this test for malaria. I will demonstrate a rapid malaria test to you now.
Interviewer: Demonstrate an RDT—explain what will happen if there are malaria parasites in the blood.
The benefits of doing a malaria test before treatment is that the ill person can get the right treatment for his/her illness. If the test
shows malaria, the ill person should be treated with an ACT such as Co-artem which will likely cure a patient. If the test does not
show malaria, then they do not need an ACT such as Co-artem and an alternative diagnosis and treatment must be determined.
If a malaria test is not performed then nobody can be sure whether or not a fever is malaria and whether or not the antimalarial
treatment is necessary or not.
You have come today to a drug seller to buy antimalarial drugs. The drug seller recommends you to buy and carry out a rapid malaria
test which will tell you if you actually have malaria. The drug seller explains that he/she will recommend different treatments
depending on the result of the rapid malaria test. These are the following:
(A) If the rapid malaria test shows malaria, then he/she will recommend a course of Co-artem which is available at 15000 Shillings,
or
(B) If the rapid malaria test shows that your illness is not malaria, then depending on how sick you are, the drug seller will suggest
either a course of paracetamol available at 1000 shillings for a simple fever or refer to a health centre/unit for a serious fever.
If drug shops had rapid malaria tests available today—would you be willing to pay UGX500 for a rapid diagnostic test?
Scenario 3: A course of ACT after a positive RDT
Assume that you have come to a drug shop today because you think that you may have malaria but you are not sure. You are
therefore considering buying drugs against malaria. You buy a rapid malaria test at the price of 1000 Shillings. The test shows that
you have malaria. The drug seller offers you to buy a course of Co-artem explaining that this is the best drug at the market at
present.
If you know that you have malaria after taking a rapid malaria test and drug shops had Co-artem available today—would you be
willing to pay UGX2000 for a course of Co-artem to treat one attack of malaria?
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